Nelfinavir Mesylate: A Protease Inhibitor

  title={Nelfinavir Mesylate: A Protease Inhibitor},
  author={Vinita B. Pai and Milap C. Nahata},
  booktitle={The Annals of pharmacotherapy},
  • V. PaiM. Nahata
  • Published in The Annals of pharmacotherapy 1 March 1999
  • Medicine
OBJECTIVE: To review the clinical pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of nelfinavir mesylate. DATA SOURCE: A MEDLINE search restricted to English-language literature from January 1966 to February 1998 and an extensive review of journals was conducted to prepare this article. MeSH headings included protease inhibitors, nelfinavir mesylate, and AG1343. Abstracts presented at meetings and data submitted to the Food and Drug… 

Figures and Tables from this paper

Clinical Pharmacology and Pharmacokinetics of Amprenavir

The clinical pharmacology, exposure—activity relationship, and drug resistance profile of amprenavir support the use of this potent HIV protease inhibitors in combination antiretroviral regimens, especially for persons who have experienced virologic failure while on protease inhibitor—containing regimens.

Nelfinavir: an update on its use in HIV infection.

Nelfinavir is effective in limiting HIV replication and increasing CD4+ cell counts in HIV-infected adults and children and should be considered as a first-line option in protease inhibitor-naive patients and in those unable to tolerate other protease inhibitors.

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir

Since orally available nelfinavir has been a safe drug of choice for both adult and pediatric HIV-infected patients for over two decades, exploiting its anti-cancer off-target effects will enable fast-tracking this newer option into the existing repertoire of cancer chemotherapeutics.

Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity

The analysis of controversies on the molecular mechanisms of NFV hints to the possibility that NFV works in a different way in tumor cells and in hepatocytes and adipocytes, in order to find an appropriate place for NFV in cancer treatment.

Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity.

The analysis of controversies on the molecular mechanisms of NFV hints to the possibility that NFV works in a different way in tumor cells and in hepatocytes and adipocytes, in order to find an appropriate place for NFV in cancer treatment.

Nelfinavir , ALeadHIVProtease Inhibitor , Is aBroad-Spectrum , AnticancerAgent that InducesEndoplasmicReticulum Stress , Autophagy , andApoptosis Invitro and Invivo

Nelfinavir is a lead HIV protease inhibitor with pleiotropic effects in cancer cells, and is a Food and Drug Administration approved drug that could be repositioned as a cancer therapeutic.

A review of nelfinavir for the treatment of HIV infection

NFV has favourable characteristics that make it a suitable antiretroviral compound for many HIV-infected patients and it can be used in patients who do not tolerate ritonavir even at low doses, and it is well tolerated in pregnant women, has a low-grade interaction with methadone and may be well tolerable in hepatitis C virus-co- infected patients.

Nelfinavir in Expanded Postexposure Prophylaxis Causing Acute Hepatitis With Cholestatic Features TWo Case Reports

To the Editor: Two medical professionals treated with postexposure prophylaxis (PEP) after exposure to human immunodeficiency virus (HIV) and hepatitis C virus (HCV) developed hepatotoxicity probably

Effects of nelfinavir and its M8 metabolite on lymphocyte P‐glycoprotein activity during antiretroviral therapy

It is likely that CD4+ and CD8+ lymphocytes in patients receiving nelfinavir as therapy for human immunodeficiency virus may have P‐glycoprotein inhibited by plasma concentrations of nelf Scandinavir.

Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy-tert-Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1

The population pharmacokinetic model describing the dispositions of NFV and M8 should facilitate the design of future studies to elucidate the relative contributions of the parent compound and M9 to the pharmacological and toxic effects of NFVs therapy.



The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

This study demonstrates that when patients are coadministered NVP there is a 50% reduction in the plasma AUC of NFV, which is currently being used in combination therapy with protease inhibitors for antiretroviral-experienced patients in the setting of treatment failure.

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV‐infected patients

NLF increases the oral bioavailability of SQV (hard gel) approximately fivefold, and for some patients the addition of NLF to SQV will increase the drug levels from subtherapeutic to the therapeutic range.

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

  • J. VaccaB. Dorsey E. Roth
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1994
L-735,524 is a potent inhibitor of virus replication in cell culture and inhibits the protease-mediated cleavage of the viral precursor polyproteins that results in the production of noninfectious progeny viral particles.

Preformulation studies of a novel HIV protease inhibitor, AG1343.

Formulation into several prototypical oral dosage forms for in-vitro evaluation in animal models prior to phase I clinical trials resulted in a several-fold difference in bioavailability between these formulations.

Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease

Results from these studies demonstrate that AG1343 is orally bioavailable and that levels in plasma in the therapeutic range are achievable and are maintained for prolonged periods in the animal models tested and for further testing in human subjects.

HIV protease inhibitors: their anti-HIV activity and potential role in treatment.

Preclinical studies indicate that protease inhibitors prevent the maturation of immature viral particles into infectious virions and thereby limit the spread of HIV in cell cultures, and Laboratory data have also shown that these agents have good toxic-effect profiles, and recent improvements have resulted in compounds that are more bioavailable.

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

The potent anti-HIV activity of AG1343 against several isolates suggests thatAG1343 should perform well during ongoing human phase II clinical trials.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor

The level of resistance did not increase following continued passage in increasing concentrations of drug, and the resistant virus retained its drug susceptibility phenotype 34 days after drug withdrawal, according to genotypic analysis.

Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

Human immunodeficiency virus type 1 (HIV-1)-specific pyridinone reverse transcriptase (RT) inhibitors prevent HIV-1 replication in cell culture and may all make up a single pharmacologic class of RT inhibitor.

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

In vitro selection of viral variants with decreased sensitivity to a C2-symmetric protease inhibitor results in a substantial decrease in the inhibitory activity of the drug on the enzyme and a comparable increase in viral resistance.